These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 22683336

  • 1. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine.
    Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ.
    J Neuroimmunol; 2012 Sep 15; 250(1-2):94-8. PubMed ID: 22683336
    [Abstract] [Full Text] [Related]

  • 2. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A.
    Nat Med; 2001 Mar 15; 7(3):365-8. PubMed ID: 11231638
    [Abstract] [Full Text] [Related]

  • 3. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Martínez-Martínez P, De Baets MH, Losen M.
    Autoimmunity; 2010 Aug 15; 43(5-6):353-70. PubMed ID: 20380584
    [Abstract] [Full Text] [Related]

  • 4. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN, Reddel SW, Gervásio OL, Phillips WD.
    Ann Neurol; 2008 Jun 15; 63(6):782-9. PubMed ID: 18384168
    [Abstract] [Full Text] [Related]

  • 5. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.
    Vincent A, Newsom-Davis J.
    Clin Exp Immunol; 1982 Aug 15; 49(2):266-72. PubMed ID: 7127905
    [Abstract] [Full Text] [Related]

  • 6. Myasthenia gravis patients with anti-MuSK antibodies.
    Zagar M, Vranjes D, Sostarko M, Vogrinc Z, Bilić E, Trbojević Cepe M.
    Coll Antropol; 2009 Dec 15; 33(4):1151-4. PubMed ID: 20102061
    [Abstract] [Full Text] [Related]

  • 7. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K.
    Ann Neurol; 2005 Feb 15; 57(2):289-93. PubMed ID: 15668981
    [Abstract] [Full Text] [Related]

  • 8. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
    Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G.
    Neurology; 2007 Feb 20; 68(8):609-11. PubMed ID: 17310034
    [Abstract] [Full Text] [Related]

  • 9. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB, Hunt CH, Batish SD.
    Arch Neurol; 2005 Jun 20; 62(6):1002-3. PubMed ID: 15956173
    [Abstract] [Full Text] [Related]

  • 10. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.
    Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A.
    Neurology; 2005 Feb 08; 64(3):536-8. PubMed ID: 15699390
    [Abstract] [Full Text] [Related]

  • 11. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K, Konishi T, Ohta M.
    Nihon Rinsho; 2008 Jun 08; 66(6):1149-54. PubMed ID: 18540361
    [Abstract] [Full Text] [Related]

  • 12. The pathophysiology of penicillamine-induced myasthenia gravis.
    Kuncl RW, Pestronk A, Drachman DB, Rechthand E.
    Ann Neurol; 1986 Dec 08; 20(6):740-4. PubMed ID: 3813503
    [Abstract] [Full Text] [Related]

  • 13. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.
    Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB.
    Muscle Nerve; 2004 Jul 08; 30(1):55-60. PubMed ID: 15221879
    [Abstract] [Full Text] [Related]

  • 14. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
    Plomp JJ, Huijbers MG, van der Maarel SM, Verschuuren JJ.
    Ann N Y Acad Sci; 2012 Dec 08; 1275():114-22. PubMed ID: 23278586
    [Abstract] [Full Text] [Related]

  • 15. [Acetylcholine receptor antibody in D-penicillamine therapy].
    Kolarz G, Maida EM.
    Z Rheumatol; 1986 Dec 08; 45(3):118-21. PubMed ID: 3751350
    [Abstract] [Full Text] [Related]

  • 16. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, Hilton-Jones D, Matthews PM, Vincent A.
    Brain; 2006 Jun 08; 129(Pt 6):1481-92. PubMed ID: 16672291
    [Abstract] [Full Text] [Related]

  • 17. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
    Maruyama N, Shigemoto K.
    Rinsho Shinkeigaku; 2007 Nov 08; 47(11):842-4. PubMed ID: 18210813
    [Abstract] [Full Text] [Related]

  • 18. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P, De Baets MH, Martínez-Martínez P.
    Autoimmunity; 2010 Aug 08; 43(5-6):380-400. PubMed ID: 20380581
    [Abstract] [Full Text] [Related]

  • 19. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
    Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L.
    Arch Neurol; 2012 Apr 08; 69(4):445-51. PubMed ID: 22158716
    [Abstract] [Full Text] [Related]

  • 20. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis.
    Tzartos SJ, Morel E, Efthimiadis A, Bustarret AF, D'Anglejan J, Drosos AA, Moutsopoulos HA.
    Clin Exp Immunol; 1988 Oct 08; 74(1):80-6. PubMed ID: 2464451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.